Edgewise Therapeutics faces challenges with DMD/BMD programs, upcoming trial data concerns, and competitive risks.

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

RegenXBio has shared updated phase 1/2 data on its Duchenne muscular dystrophy (DMD) gene therapy, providing evidence that ...

Advancements in gene therapy for Duchenne muscular dystrophy (DMD) have improved the outlook for some patients, but further ...

Repurposing existing therapies may help slow muscle weakness in patients with Duchenne muscular dystrophy, a new study ...

“Nomination and acceleration of PBGENE-DMD as our second wholly owned program is a result of the compelling preclinical evidence we have generated to date,” said Michael Amoroso, President and ...

DURHAM, N.C., May 14, 2025--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo ...

Entrada Therapeutics has secured the Health Authorities and Ethics Committees' authorisation within the European Union (EU) ...

Diagnosed with Duchenne muscular dystrophy (DMD) at three years old, Dr Jon Hastie grew up never thinking about the future – until one day he discovered he actually had one. Now in his 30s ...

Italfarmaco’s oral HDAC inhibitor givinostat has been approved in the US as a treatment for Duchenne muscular dystrophy (DMD), becoming the first non-steroidal option for patients with all ...

DUVYZAT ® (givinostat) is a histone deacetylase (HDAC) inhibitor indicated for the treatment of patients six years of age and older with DMD. Please see the Indication and Important Safety ...